232
MOLECULAR AND CLINICAL ONCOLOGY 3: 232-236, 2015
Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer BIAO GENG1, MAN-MAN LIANG2, XIAO-BING YE1 and WEN-YING ZHAO1 Departments of 1Medical Oncology and 2Internal Medicine, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China Received July 31, 2014; Accepted September 4, 2014 DOI: 10.3892/mco.2014.419 Abstract. The objective of this study was to investigate the association of serum cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) levels with clinicopathological parameters in patients diagnosed with metastatic breast cancer (MBC). We retrospectively evaluated the medical records of 284 patients diagnosed with MBC between January, 2007 and December, 2012 who fulfilled the specified criteria and the association between the levels of the two tumor marker and clinicopathological parameters was analyzed. Of the 284 patients, elevated CA 15-3 and CEA levels at initial diagnosis of recurrence were identified in 163 (57.4%) and 97 (34.2%) patients, respectively. Elevated CA 15-3 and CEA levels were significantly associated with breast cancer molecular subtypes (P
MOLECULAR AND CLINICAL ONCOLOGY 3: 232-236, 2015
Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer BIAO GENG1, MAN-MAN LIANG2, XIAO-BING YE1 and WEN-YING ZHAO1 Departments of 1Medical Oncology and 2Internal Medicine, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China Received July 31, 2014; Accepted September 4, 2014 DOI: 10.3892/mco.2014.419 Abstract. The objective of this study was to investigate the association of serum cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) levels with clinicopathological parameters in patients diagnosed with metastatic breast cancer (MBC). We retrospectively evaluated the medical records of 284 patients diagnosed with MBC between January, 2007 and December, 2012 who fulfilled the specified criteria and the association between the levels of the two tumor marker and clinicopathological parameters was analyzed. Of the 284 patients, elevated CA 15-3 and CEA levels at initial diagnosis of recurrence were identified in 163 (57.4%) and 97 (34.2%) patients, respectively. Elevated CA 15-3 and CEA levels were significantly associated with breast cancer molecular subtypes (P
